RVAC Medicines Zhenjiang Pengbo Biotechnology

RVAC Medicines is a clinical-stage biotechnology company specializing in the development of messenger RNA (mRNA) therapeutics and vaccines. Headquartered in Singapore with significant R&D and manufacturing operations in China and the United States, the company leverages its proprietary mRNA platform and lipid nanoparticle (LNP) delivery technology. Its primary focus is on infectious diseases, including COVID-19 and respiratory syncytial virus (RSV), as well as potential applications in oncology and rare diseases. RVAC Medicines was incubated by CBC Group and aims to address unmet medical needs globally through its end-to-end mRNA capabilities, from discovery to commercial-scale GMP manufacturing.